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The manufacturing and storage of the piperacillin produce different impurities of various 
concentrations, which may influence the efficacy and safety of the drug. Since no report of genotoxicity 
data is available on the impurities of piperacillin, further studies were designed and conducted to 
provide information for establishing the safety profile and qualification of the piperacillin impurity-A. 
Salmonella typhimurium strains were exposed to Piperacillin impurity-A for Ames tests. Neither 
increase in number of revertants indicative of mutagenic activity nor inhibition of bacterial growth, 
indicative of cytotoxicity were observed up to 5 mg/plate both in the presence and absence of metabolic 
activation. Similarly, chromosomal aberration assay did not reveal any significant alterations up to 5 
mg/culture as compared to the negative control both in the presence and absence of metabolic 
activation (S9 mix). The results of these studies indicate that Piperacillin impurity-A is non-mutagenic in 
Ames test and non-clastogenic in chromosomal aberration study. 
 






There is a growing concern about the role of impurities in 
drug substances. Safety regulations require insight into 
the structure and the amount of impurities present in the 
drug substance before they can be administered to 
humans. The presence of small amounts of impurities 
may influence the efficacy and safety of Piperacillin. The 
manufacturing and storage process produce impurities at 
various concentrations and occasionally, the concentra-
tion of these impurities crosses the threshold limit and 
warrants for establishing the safety profile (ICH Guide-
line, 2000a; Federal Register, 2000b). 
Piperacillin an antibiotic of the penicillin group is widely 
used against a large number of gram-positive and gram-
negative microorganisms (AHFS Drug Information, 2002). 
Various impurities of Piperacillin are reported in 
PHARMEUROPA (2002). However, no genotoxicity data 
is available on impurities. Piperacillin impurity-A is a pro-
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during manufacturing and storage process. As the level 
of this impurity is comparatively higher and failed to pass 
the validation criteria of computer-assisted toxicity predic-
tion carried out by “Topkat” software, the present geno-
toxic studies were designed and conducted to provide the 
information for establishing the safety profile and 
qualification of the impurity.  
 
 
MATERIALS AND METHODS 
 
Structure of piperacillin impurity-A 
 
The structure of piperaciilin impurity-A given in Figure 1 was 
identified and characterized using LC- MS and NMR. The selected 
Piperacillin impurity-A was isolated with HPLC purity of 92.56% and 
molecular weight of 715.8, with molecular formula C31H37N7O9S2. 




[3.2.0] heptane-2-carboxylic acid.  It was subjected to in vitro 
genotoxicity screening for the qualification of impurity as per the 
ICH recommendation (ANDAs impurities in drug products 1998; 














Dimethyl sulfoxide (DMSO- CAS no. 67-68-5), nicotinamide 
adeninedinucleotide phosphate sodium salt (NADP-CAS no 214-
664-6), D-glucose-6-phosphate disodium salt (CAS no 3671-99-6), 
L-histidine monohydrate (CAS no 7048-02-4), d-biotin (CAS no 58-
85-5) were purchased from Sigma Chemical Company and Minimal 
Essential Medium (MEM CAT no 41090-036) procured from Gibco. 
Standard mutagens; 2-aminofluorene (CAS no 613-13-8), 
mitomycin C (CAS no 56-07-7), 4-nitroquinolene-1-Oxide (CAS no 
56-57-5), sodium azide (CAS no 26628-22-8) and benzo(a)pyrene 
(CAS no 200-028-5) were also obtained from Sigma. Oxoid Nutrient 
Broth No. 2 (Oxoid) and Difco Bacto Agar (Difco) were used for the 





Salmonella typhimurium strains TA97a, TA98, TA100, TA1535 and 
TA102 were obtained from Bruce Ames Laboratory, Molecular and 
Cell Biology, University of California, and checked for their viable 
counts and genotype characteristics. Plate incorporation method 
(Maron and Ames, 1983) using histidine-dependent strains of S. 
typhimurium TA 97a, TA 98, TA 100, TA 102 and TA 1535 in the 
presence and absence of metabolic activation system (S9 liver 
fraction) was adopted for assessing the mutagenicity.   
Based on the results of cytotoxicity test, piperacllin impurity-A 
was tested for its mutagenic properties at five different concentra-
tions viz., 5, 2.5, 1.25, and 0.625 mg/plate. 100 µl of various 
concentrations of impurity dissolved in dimethyl sulfoxide were 
added to 2 ml top agar mixed with 100 µl of bacterial culture and 
then poured on to a plate containing minimal glucose agar. These 
plates were incubated at 37oC for 48 h and his+ revertant colonies 
were manually counted and the results were shown as the mean of 
the three plates with standard deviation. The influence of metabolic 
activation was tested by adding 500 µl of S9 mixture. The experi-
ments were analysed in triplicate and was repeated again to 
confirm the result. The criteria employed to interpret the results of 
Ames test as positive were similar to those used in regulatory 
guidelines (OECD and ICH Guidelines). The number of induced 
mutation should be at least twice the activity observed in negative 
control and there must be a reproducible dose response curve. 
Concurrent positive and negative (dimethyl sulfoxide) controls were 
used in the study. The standard mutagens used as positive controls 
in each experiment were without metabolic activation, 4-nitro-
quinoline 1- Oxide (5 g/plate) for strain TA 97a and TA98, Sodium 
azide (5 g/plate) for strain TA 100 and TA 1535, Mitomycin-C 
(0.02 mg/plate) for TA 102. In case of positive controls with meta- 
bolic   activation,   2-aminoflurene  (20 g/plate)  for  TA97a,  TA98, 




TA100, TA 1535 and TA 102. 
 
 
Chromosomal aberration assay 
 
Chinese Hamster Ovary cell line obtained from National Centre for 
Cell Science, Pune were used for in vitro chromosomal aberration 
study. Monolayer cultures of 80% confluency were cultured at a cell 
density of 2.3 x 105 cells per culture and 24 h after culturing, the 
cells were exposed to the test substance with and without Aroclor 
1254 – induced wistar rats S-9 (Venitt et al., 1990). As no 
precipitation and reduced mitotic index were recorded for impurity of 
piperacillin at 5 mg/culture, dose levels of 5, 2.5 and 1.25 
mg/culture were selected and exposed to cell cultures in duplicate 
(U.S. Environmental Protection Agency, 1998). Concurrent positive 
controls mitomycin-C with out S-9 and benzo(A)pyrene with S-9 and 
negative control (DMSO) were used for the study. Cell cultures 
were incubated at 37oC, harvested at 18 h after exposure and the 
cells were stained with 5% Giemsa. A total of about 200 meta-
phases were observed for structural chromosome aberrations, 
including both chromosomes and chromatids (that is, break, 
deletion, fragments and exchanges) were recorded. Gaps were 
recorded but not included in the aberration frequency. 
 
 
RESULTS AND DISCUSSION 
 
All the strains of S. typhimurium; TA 97a, TA 98, TA 100, 
TA 102 and TA 1535, exposed to different concentrations 
of Piperacillin impurity-A, did not show two fold or greater 
increase in the mean number of revertants as compared 
to negative control group given in Table 1. All strains 
used in the study exhibited marked increase (>10 fold) in 
the number of revertants when treated with positive 
control agents. The results confirmed the sensitivity of the 
tester strains to mutagens and thus the validity of the 
assay. The results indicated that the mean number of 
histidine revertants in the treatment groups were 
comparable to the mean number of revertants in the 
negative control group in all the five S. typhimurium tester 
strains viz., TA 97a, TA 98, TA 100, TA 102 and TA 1535 
both in the absence and presence of metabolic activation. 
The impurity of piperacillin up to 5 mg/plate in the 
presence and absence of metabolic activation was found 
to be non-mutagenic to all the five S. typhimurium tester 
strains.  
Similarly in vitro chromosomal aberration assay did not 
reveal any significant alterations up to 5 mg/culture given 
in Table 2 as compared to the negative control both in the 
presence and absence of metabolic activation (S9 mix) 
but the positive controls induced aberration. The 
chromosomal aberrations recorded per cell in the 
presence of metabolic activation was 0.01, 0.00 and 0.00 
at 5, 2.5 and 1.25 mg per culture respectively and 0.01 in 
vehicle control and 0.08 in the positive control group. The 
number of chromosomal aberrations per cell recorded in 
the absence of metabolic activation was 0.01, 0.00 and 
0.00 at 5, 2.5 and 1.25 mg per culture respectively, 0.01 
in vehicle control and 0.08 in the positive control group. 
Piperacillin impurity-A up to 5 mg/ml is found to be non-
clastogenic to Chinese Hamster Ovary cell lines both in 
the presence and absence of metabolic activation. 
 




Table 1. Mean plate count of mutagenicity study. 
 
Revertant colonies / Plate (Mean 9n = 3) ± S. D.) 
TA 97a TA 98 TA 1535 TA 100 TA 102 
Dose 
Levels 
(µg/plate) -S9 +S9 -S9 +S9 -S9 +S9 -S9 +S9 -S9 +S9 
NC (DMSO) 180±4 175± 6 44±3 49±7 16±2 17±3 175±6 177±10 298±7 300±9 
5 180±7 185±2 39±3 45±4 15±5 20±7 174±10 183±11 302±7 293±7 
2.5 177±6 192±3 39±4 44±6 18±3 19±2 182±4 183±10 295±6 304±7 
1.25 178±7 182±3 44±3 40±5 18±3 17±5 185±6 177±9 300±10 296±4 
0.625 181±2 182±3 41±7 44±4 15±4 20±2 182±7 185±5 301±6 303±4 
PC SA NA NA NA NA 1228±45 NA 2251±69 NA NA NA 
PC 4NQNO 1891±15 NA 842±53 NA NA NA NA NA NA NA 
PC MMC NA NA NA NA NA NA NA NA 3435±63 NA 
PC 2AF NA 2202±16 NA 1517±40 NA 721±21 NA 2719±28 NA 3176±54 
 
Key: µg = microgram, S.D. = Standard deviation, NC = Negative control, DMSO = Dimethyl sulfoxide PC = Positive control, 4NQNO = 
4Nitroquinolene N Oxide, SA = Sodium azide, MMC = Mitomycin C, 2AF = 2Aminofluorene, NA = Not Applicable 
 
 
Table 2. Summary of chromosomal aberration assay in CHO cell line. 
 
Break analysis 
Type of aberrations Dose (mg/ 
culture) 
S9 Total N° of 
metaphases 
analyzed 
TotaL N° of aberrations 
Gap Chromatid Chromosome 
Total cells with aberrations Aberrations/ cell % Cells with aberratons
- 200 1 1 0 0 1 0.01 1 NC 
(DMSO) + 200 0 0 0 0 0 0.00 0 
- 200 1 1 0 0 1 0.01 1 
5 
+ 200 0 0 0 0 0 0.00 0 
- 200 0 0 0 0 0 0.00 0 
2.5 
+ 200 0 0 0 0 0 0.00 0 
- 200 0 0 0 0 0 0.00 0 
1.25 
+ 200 0 0 0 0 0 0.00 0 
2.5 µg/ml (MIT) - 200 8 4 0 4 8 0.08* 8* 
0.03 µg/ml (BP) + 200 7 5 0 3 8 0.08* 8* 
 
BP = Benzo(A) pyrene (S9+), NC = Normal control, DMSO = Dimethyl sulfoxide, MIT = Mitomycin-C (S9-), N° = number.  
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